|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HPN |
Gene summary for HPN |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HPN | Gene ID | 3249 |
| Gene name | hepsin | |
| Gene Alias | TMPRSS1 | |
| Cytomap | 19q13.11 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | A0A140VJK9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3249 | HPN | NAFLD1 | Human | Liver | NAFLD | 3.97e-16 | 1.41e+00 | -0.04 |
| 3249 | HPN | S43 | Human | Liver | Cirrhotic | 1.63e-13 | -2.72e-01 | -0.0187 |
| 3249 | HPN | HCC1_Meng | Human | Liver | HCC | 2.76e-76 | -4.64e-02 | 0.0246 |
| 3249 | HPN | HCC2_Meng | Human | Liver | HCC | 1.48e-14 | -3.86e-01 | 0.0107 |
| 3249 | HPN | cirrhotic1 | Human | Liver | Cirrhotic | 1.03e-07 | -2.23e-01 | 0.0202 |
| 3249 | HPN | cirrhotic2 | Human | Liver | Cirrhotic | 1.02e-06 | -1.54e-01 | 0.0201 |
| 3249 | HPN | cirrhotic3 | Human | Liver | Cirrhotic | 6.16e-03 | -2.40e-01 | 0.0215 |
| 3249 | HPN | HCC2 | Human | Liver | HCC | 1.51e-15 | 3.60e+00 | 0.5341 |
| 3249 | HPN | Pt13.a | Human | Liver | HCC | 2.93e-02 | -1.33e-01 | 0.021 |
| 3249 | HPN | Pt13.b | Human | Liver | HCC | 7.69e-27 | 1.98e-02 | 0.0251 |
| 3249 | HPN | Pt14.a | Human | Liver | HCC | 6.99e-05 | 1.28e-01 | 0.0169 |
| 3249 | HPN | Pt14.b | Human | Liver | HCC | 5.71e-07 | 7.69e-02 | 0.018 |
| 3249 | HPN | S027 | Human | Liver | HCC | 4.27e-20 | 1.90e+00 | 0.2446 |
| 3249 | HPN | S028 | Human | Liver | HCC | 1.10e-38 | 1.98e+00 | 0.2503 |
| 3249 | HPN | S029 | Human | Liver | HCC | 3.43e-40 | 2.54e+00 | 0.2581 |
| 3249 | HPN | male-WTA | Human | Thyroid | PTC | 5.31e-35 | 4.60e-01 | 0.1037 |
| 3249 | HPN | PTC01 | Human | Thyroid | PTC | 7.69e-26 | 4.86e-01 | 0.1899 |
| 3249 | HPN | PTC03 | Human | Thyroid | PTC | 5.36e-04 | 3.63e-01 | 0.1784 |
| 3249 | HPN | PTC04 | Human | Thyroid | PTC | 3.27e-07 | 2.05e-01 | 0.1927 |
| 3249 | HPN | PTC05 | Human | Thyroid | PTC | 1.42e-26 | 9.08e-01 | 0.2065 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003003815 | Endometrium | AEH | contractile actin filament bundle assembly | 28/2100 | 106/18723 | 1.08e-05 | 2.45e-04 | 28 |
| GO:004314915 | Endometrium | AEH | stress fiber assembly | 28/2100 | 106/18723 | 1.08e-05 | 2.45e-04 | 28 |
| GO:005149216 | Endometrium | AEH | regulation of stress fiber assembly | 24/2100 | 91/18723 | 4.61e-05 | 7.68e-04 | 24 |
| GO:011002016 | Endometrium | AEH | regulation of actomyosin structure organization | 25/2100 | 100/18723 | 8.41e-05 | 1.25e-03 | 25 |
| GO:001063910 | Endometrium | AEH | negative regulation of organelle organization | 61/2100 | 348/18723 | 2.65e-04 | 3.09e-03 | 61 |
| GO:00514949 | Endometrium | AEH | negative regulation of cytoskeleton organization | 32/2100 | 163/18723 | 1.12e-03 | 9.74e-03 | 32 |
| GO:00322325 | Endometrium | AEH | negative regulation of actin filament bundle assembly | 10/2100 | 35/18723 | 4.04e-03 | 2.69e-02 | 10 |
| GO:00514975 | Endometrium | AEH | negative regulation of stress fiber assembly | 9/2100 | 32/18723 | 7.02e-03 | 4.07e-02 | 9 |
| GO:003297017 | Endometrium | EEC | regulation of actin filament-based process | 89/2168 | 397/18723 | 4.76e-10 | 4.76e-08 | 89 |
| GO:000701517 | Endometrium | EEC | actin filament organization | 95/2168 | 442/18723 | 1.31e-09 | 1.09e-07 | 95 |
| GO:190290317 | Endometrium | EEC | regulation of supramolecular fiber organization | 82/2168 | 383/18723 | 2.11e-08 | 1.25e-06 | 82 |
| GO:003295617 | Endometrium | EEC | regulation of actin cytoskeleton organization | 77/2168 | 358/18723 | 4.62e-08 | 2.52e-06 | 77 |
| GO:003103214 | Endometrium | EEC | actomyosin structure organization | 46/2168 | 196/18723 | 1.94e-06 | 5.80e-05 | 46 |
| GO:011005317 | Endometrium | EEC | regulation of actin filament organization | 59/2168 | 278/18723 | 2.62e-06 | 7.53e-05 | 59 |
| GO:190290415 | Endometrium | EEC | negative regulation of supramolecular fiber organization | 40/2168 | 167/18723 | 5.23e-06 | 1.28e-04 | 40 |
| GO:005101717 | Endometrium | EEC | actin filament bundle assembly | 37/2168 | 157/18723 | 1.71e-05 | 3.26e-04 | 37 |
| GO:006157217 | Endometrium | EEC | actin filament bundle organization | 37/2168 | 161/18723 | 3.09e-05 | 5.34e-04 | 37 |
| GO:003003816 | Endometrium | EEC | contractile actin filament bundle assembly | 27/2168 | 106/18723 | 5.47e-05 | 8.64e-04 | 27 |
| GO:004314916 | Endometrium | EEC | stress fiber assembly | 27/2168 | 106/18723 | 5.47e-05 | 8.64e-04 | 27 |
| GO:001063915 | Endometrium | EEC | negative regulation of organelle organization | 64/2168 | 348/18723 | 1.15e-04 | 1.55e-03 | 64 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05203 | Liver | Cirrhotic | Viral carcinogenesis | 76/2530 | 204/8465 | 1.34e-02 | 4.20e-02 | 2.59e-02 | 76 |
| hsa052031 | Liver | Cirrhotic | Viral carcinogenesis | 76/2530 | 204/8465 | 1.34e-02 | 4.20e-02 | 2.59e-02 | 76 |
| hsa052032 | Liver | HCC | Viral carcinogenesis | 117/4020 | 204/8465 | 2.68e-03 | 8.98e-03 | 5.00e-03 | 117 |
| hsa052033 | Liver | HCC | Viral carcinogenesis | 117/4020 | 204/8465 | 2.68e-03 | 8.98e-03 | 5.00e-03 | 117 |
| hsa0520323 | Prostate | Tumor | Viral carcinogenesis | 70/1791 | 204/8465 | 7.53e-06 | 6.56e-05 | 4.07e-05 | 70 |
| hsa0520333 | Prostate | Tumor | Viral carcinogenesis | 70/1791 | 204/8465 | 7.53e-06 | 6.56e-05 | 4.07e-05 | 70 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HPN | SNV | Missense_Mutation | novel | c.1232N>A | p.Ser411Asn | p.S411N | P05981 | protein_coding | tolerated(0.22) | benign(0) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| HPN | SNV | Missense_Mutation | c.721N>T | p.Gly241Trp | p.G241W | P05981 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-EW-A6S9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| HPN | SNV | Missense_Mutation | rs751620154 | c.484N>T | p.Arg162Cys | p.R162C | P05981 | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-PE-A5DD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | CR | |
| HPN | SNV | Missense_Mutation | novel | c.281G>T | p.Gly94Val | p.G94V | P05981 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-S3-AA10-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
| HPN | insertion | Frame_Shift_Ins | novel | c.105_118+8dupATCCTGGGCCATTGGTGAGAGC | P05981 | protein_coding | TCGA-B6-A0I6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||||
| HPN | SNV | Missense_Mutation | novel | c.407N>T | p.Ser136Phe | p.S136F | P05981 | protein_coding | tolerated(0.68) | benign(0.007) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| HPN | SNV | Missense_Mutation | rs753366151 | c.1223N>T | p.Ser408Phe | p.S408F | P05981 | protein_coding | deleterious(0.02) | possibly_damaging(0.806) | TCGA-EK-A3GM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| HPN | SNV | Missense_Mutation | c.341C>T | p.Thr114Met | p.T114M | P05981 | protein_coding | deleterious(0.01) | probably_damaging(0.979) | TCGA-AA-3489-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| HPN | SNV | Missense_Mutation | rs374894952 | c.641N>A | p.Arg214Gln | p.R214Q | P05981 | protein_coding | tolerated(0.07) | benign(0.089) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
| HPN | SNV | Missense_Mutation | c.112G>C | p.Ala38Pro | p.A38P | P05981 | protein_coding | deleterious(0.01) | possibly_damaging(0.694) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 3249 | HPN | DRUGGABLE GENOME, PROTEASE, CELL SURFACE | BENTIROMIDE | BENTIROMIDE | ||
| 3249 | HPN | DRUGGABLE GENOME, PROTEASE, CELL SURFACE | AC1LFXA6 | |||
| 3249 | HPN | DRUGGABLE GENOME, PROTEASE, CELL SURFACE | N-Methyl-D-aspartic acid | |||
| 3249 | HPN | DRUGGABLE GENOME, PROTEASE, CELL SURFACE | Meclizine | MECLIZINE | ||
| 3249 | HPN | DRUGGABLE GENOME, PROTEASE, CELL SURFACE | BENTIROMIDE | BENTIROMIDE |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |